https://www.selleckchem.com/pr....oducts/VX-680(MK-045
73 to -3.15, P 0.00001) for SDS score, pramipexole therapy also decreased SAS score markedly (P 0.0001). Compared with control group, the pooled effects of pramipexole on motor UPDRS score and activities of daily living UPDRS score were statistically significant (P 0.01). Furthermore, pramipexole therapy didn't increase the number of any adverse events in dPD patients (RR 0.72, 95 % CI 0.37-1.41, P = 0.34). Pramipexole therapy can alleviate depressive symptoms and motor dysfunction in dPD patients, and there were
Like
Comment
Share
